Gu T - Search Results

1

Sequential CD7 CAR T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.

Hu Y, Zhang M, Yang T, Mo Z, Wei G, Jing R, Zhao H, Chen R, Zu C, Gu T, Xiao P, Hong R, Feng J, Fu S, Kong D, Xu H, Cui J, Huang S, Liang B, Yuan X, Cui Q, Guo H, Yu Y, Feng Y, Jin C, Ren J, Chang AH, Wang D, Huang H. Hu Y, et al. Among authors: gu t. N Engl J Med. 2024 Apr 25;390(16):1467-1480. doi: 10.1056/NEJMoa2313812. N Engl J Med. 2024. PMID: 38657244

2

Daratumumab Prevents Experimental Xenogeneic Graft-Versus-Host Disease by Skewing Proportions of T Cell Functional Subsets and Inhibiting T Cell Activation and Migration.

Gao Y, Shan W, Gu T, Zhang J, Wu Y, Li X, Zeng X, Zhou H, Chen Z, Xiao H. Gao Y, et al. Among authors: gu t. Front Immunol. 2021 Dec 20;12:785774. doi: 10.3389/fimmu.2021.785774. eCollection 2021. Front Immunol. 2021. PMID: 34987512 Free PMC article.

3

Inhibition of Calcium Signaling Prevents Exhaustion and Enhances Anti-Leukemia Efficacy of CAR-T Cells via SOCE-Calcineurin-NFAT and Glycolysis Pathways.

Shao M, Teng X, Guo X, Zhang H, Huang Y, Cui J, Si X, Ding L, Wang X, Li X, Shi J, Zhang M, Kong D, Gu T, Hu Y, Qian P, Huang H. Shao M, et al. Among authors: gu t. Adv Sci (Weinh). 2022 Mar;9(9):e2103508. doi: 10.1002/advs.202103508. Epub 2022 Jan 14. Adv Sci (Weinh). 2022. PMID: 35032108 Free PMC article.

4

Mechanisms of immune effector cell-associated neurotoxicity syndrome after CAR-T treatment.

Gu T, Hu K, Si X, Hu Y, Huang H. Gu T, et al. WIREs Mech Dis. 2022 Nov;14(6):e1576. doi: 10.1002/wsbm.1576. Epub 2022 Jul 24. WIREs Mech Dis. 2022. PMID: 35871757 Free PMC article. Review.

5

Hematologic cytopenia post CAR T cell therapy: Etiology, potential mechanisms and perspective.

Si X, Gu T, Liu L, Huang Y, Han Y, Qian P, Huang H. Si X, et al. Among authors: gu t. Cancer Lett. 2022 Dec 1;550:215920. doi: 10.1016/j.canlet.2022.215920. Epub 2022 Sep 17. Cancer Lett. 2022. PMID: 36122628 Review.

6

Novel cellular immunotherapies for hematological malignancies: recent updates from the 2021 ASH annual meeting.

Wang JN, Gu T, Hu Y, Huang H. Wang JN, et al. Among authors: gu t. Exp Hematol Oncol. 2022 Sep 24;11(1):61. doi: 10.1186/s40164-022-00316-8. Exp Hematol Oncol. 2022. PMID: 36153595 Free PMC article. Review.

7

Relapse after CAR-T cell therapy in B-cell malignancies: challenges and future approaches.

Gu T, Zhu M, Huang H, Hu Y. Gu T, et al. J Zhejiang Univ Sci B. 2022 Oct 15;23(10):793-811. doi: 10.1631/jzus.B2200256. J Zhejiang Univ Sci B. 2022. PMID: 36226535 Free PMC article. Review.

8

CAR T-cell therapies in China: rapid evolution and a bright future.

Hu Y, Feng J, Gu T, Wang L, Wang Y, Zhou L, Hong R, Tan Su Yin E, Zhang M, Lu P, Huang H. Hu Y, et al. Among authors: gu t. Lancet Haematol. 2022 Dec;9(12):e930-e941. doi: 10.1016/S2352-3026(22)00291-5. Lancet Haematol. 2022. PMID: 36455608 Review.

9

Hydrogel-based microenvironment engineering of haematopoietic stem cells.

Zhu M, Wang Q, Gu T, Han Y, Zeng X, Li J, Dong J, Huang H, Qian P. Zhu M, et al. Among authors: gu t. Cell Mol Life Sci. 2023 Jan 23;80(2):49. doi: 10.1007/s00018-023-04696-w. Cell Mol Life Sci. 2023. PMID: 36690903 Free PMC article. Review.

10

Mitochondrial isocitrate dehydrogenase impedes CAR T cell function by restraining antioxidant metabolism and histone acetylation.

Si X, Shao M, Teng X, Huang Y, Meng Y, Wu L, Wei J, Liu L, Gu T, Song J, Jing R, Zhai X, Guo X, Kong D, Wang X, Cai B, Shen Y, Zhang Z, Wang D, Hu Y, Qian P, Xiao G, Huang H. Si X, et al. Among authors: gu t. Cell Metab. 2024 Jan 2;36(1):176-192.e10. doi: 10.1016/j.cmet.2023.12.010. Cell Metab. 2024. PMID: 38171332

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,843 results

Search Page

Filters